Cargando…

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors

BACKGROUND: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs). METHODS: This prospective, observational, single-arm study evaluated long-term patient-reported outcomes for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Daneng, Darden, Christina, Osman, Noran, Sayeed, Salma, Jackson, Laurin, Garbinsky, Diana, Chauhan, Aman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575469/ https://www.ncbi.nlm.nih.gov/pubmed/36262750 http://dx.doi.org/10.2147/CMAR.S386419

Ejemplares similares

Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study
por: Morse, Michael A, et al.
Publicado: (2020)

Telotristat ethyl for carcinoid syndrome diarrhoea
Publicado: (2019)

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
por: Metz, David C, et al.
Publicado: (2020)

TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World
por: Strosberg, Jonathan, et al.
Publicado: (2019)

Telotristat ethyl reverses myxomatous changes in mice mitral valves
por: Wang, Xinmei, et al.
Publicado: (2022)

In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension
por: Jiang, Wenjun, et al.
Publicado: (2018)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
por: Pavel, Marianne, et al.
Publicado: (2018)

New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate
por: Sbardella, Emilia, et al.
Publicado: (2016)

Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study
por: Kulke, Matthew H, et al.
Publicado: (2021)

Developments in the treatment of carcinoid syndrome – impact of telotristat
por: Chan, David L, et al.
Publicado: (2018)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
por: Dillon, Joseph S., et al.
Publicado: (2020)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
por: Rendell, Marc S
Publicado: (2019)

Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review
por: Chauhan, Aman, et al.
Publicado: (2022)

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers
por: Corbett, Virginia, et al.
Publicado: (2023)

Neuroendocrine Tumors in Pediatrics
por: Farooqui, Zainab Azam, et al.
Publicado: (2019)

Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
por: Jacob, Aasems, et al.
Publicado: (2021)

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability
por: Castle, Jennifer T., et al.
Publicado: (2022)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Proposed Implementation of a Patient-Centered Self-Assessment Tool for Patients with Neuroendocrine Tumors among Academic and Community Practice Sites: The City of Hope Model
por: Crook, Christiana Joy, et al.
Publicado: (2023)

Adjuvant therapy for lung neuroendocrine neoplasms
por: Ramirez, Robert A, et al.
Publicado: (2021)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
por: Chauhan, Aman, et al.
Publicado: (2021)

Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases
por: Attiyeh, Marc A., et al.
Publicado: (2023)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States
por: Li, Daneng, et al.
Publicado: (2023)

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

Dialysis registries in the world: Korean Dialysis Registry
por: Jin, Dong-Chan
Publicado: (2015)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients
por: Nikou, George C., et al.
Publicado: (2016)

Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan
por: Masui, Toshihiko, et al.
Publicado: (2022)

Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis
por: Sun, Shenghong, et al.
Publicado: (2021)

Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective
por: Pinto, Mauricio P., et al.
Publicado: (2018)

European real world trans-catheter aortic valve implantation: systematic review and meta-analysis of European national registries
por: Krasopoulos, G., et al.
Publicado: (2016)

Calcitonin-Secreting Neuroendocrine Carcinoma of Larynx with Metastasis to Thyroid
por: LaBryer, Lauren, et al.
Publicado: (2015)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_edsci2rkidkk56hn929vvcmglk